File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions

TitleEffects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions
Authors
Issue Date2012
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
Gut, 2012, v. 61 n. 6, p. 812-818 How to Cite?
AbstractObjective: Helicobacter pylori infection and overexpression of cyclo-oxygenase-2 (COX-2) are associated with gastric cancer and its precursors. To evaluate the effect of a selective COX-2 inhibitor alone and combined with H pylori eradication on the evolution of precancerous gastric lesions, a randomised, placebocontrolled trial was conducted in Linqu County, Shandong Province, China. Methods: A total of 1024 participants aged 35-64 years with H pylori infection and advanced gastric lesions were randomly assigned in a factorial design to two interventions or placebo: anti-H pylori treatment for 7 days, and a COX-2 inhibitor (celecoxib) for 24 months. The effects of the interventions were evaluated by the regression or progression of advanced gastric lesions. Results: Of the 1024 participants who received anti-H pylori treatment or placebo, 919 completed a subsequent 24-month treatment with celecoxib or placebo. The H pylori eradication rate by per-protocol analysis was 78.2%. Compared with placebo, the proportions of regression of gastric lesions significantly increased in the celecoxib treatment (52.8% vs 41.2%) and anti-H pylori treatment (59.3% vs 41.2%) group, and OR by perprotocol analysis was 1.72 (95% CI 1.07 to 2.76) for celecoxib and 2.19 (95% CI 1.32 to 3.64) for H pylori eradication. No statistically significant effect was found for H pylori eradication followed by celecoxib on the regression of advanced gastric lesions (OR 1.48, 95% CI 0.91 to 2.40). Conclusion: This population-based intervention trial revealed that celecoxib treatment or H pylori eradication alone had beneficial effects on the regression of advanced gastric lesions. No favourable effects were seen for H pylori eradication followed by celecoxib treatment. Trial registration: HARECCTR0500053 in accordance with WHO ICTRP requirements.
Persistent Identifierhttp://hdl.handle.net/10722/163485
ISSN
2014 Impact Factor: 14.660
2014 SCImago Journal Rankings: 5.130
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, BCYen_US
dc.contributor.authorZhang, Len_US
dc.contributor.authorMa, JLen_US
dc.contributor.authorPan, KFen_US
dc.contributor.authorLi, JYen_US
dc.contributor.authorShen, Len_US
dc.contributor.authorLiu, WDen_US
dc.contributor.authorFeng, GSen_US
dc.contributor.authorZhang, XDen_US
dc.contributor.authorLi, Jen_US
dc.contributor.authorLu, APen_US
dc.contributor.authorXia, HHXen_US
dc.contributor.authorLam, Sen_US
dc.contributor.authorYou, WCen_US
dc.date.accessioned2012-09-05T05:31:53Z-
dc.date.available2012-09-05T05:31:53Z-
dc.date.issued2012en_US
dc.identifier.citationGut, 2012, v. 61 n. 6, p. 812-818en_US
dc.identifier.issn0017-5749en_US
dc.identifier.urihttp://hdl.handle.net/10722/163485-
dc.description.abstractObjective: Helicobacter pylori infection and overexpression of cyclo-oxygenase-2 (COX-2) are associated with gastric cancer and its precursors. To evaluate the effect of a selective COX-2 inhibitor alone and combined with H pylori eradication on the evolution of precancerous gastric lesions, a randomised, placebocontrolled trial was conducted in Linqu County, Shandong Province, China. Methods: A total of 1024 participants aged 35-64 years with H pylori infection and advanced gastric lesions were randomly assigned in a factorial design to two interventions or placebo: anti-H pylori treatment for 7 days, and a COX-2 inhibitor (celecoxib) for 24 months. The effects of the interventions were evaluated by the regression or progression of advanced gastric lesions. Results: Of the 1024 participants who received anti-H pylori treatment or placebo, 919 completed a subsequent 24-month treatment with celecoxib or placebo. The H pylori eradication rate by per-protocol analysis was 78.2%. Compared with placebo, the proportions of regression of gastric lesions significantly increased in the celecoxib treatment (52.8% vs 41.2%) and anti-H pylori treatment (59.3% vs 41.2%) group, and OR by perprotocol analysis was 1.72 (95% CI 1.07 to 2.76) for celecoxib and 2.19 (95% CI 1.32 to 3.64) for H pylori eradication. No statistically significant effect was found for H pylori eradication followed by celecoxib on the regression of advanced gastric lesions (OR 1.48, 95% CI 0.91 to 2.40). Conclusion: This population-based intervention trial revealed that celecoxib treatment or H pylori eradication alone had beneficial effects on the regression of advanced gastric lesions. No favourable effects were seen for H pylori eradication followed by celecoxib treatment. Trial registration: HARECCTR0500053 in accordance with WHO ICTRP requirements.en_US
dc.languageengen_US
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/en_US
dc.relation.ispartofGuten_US
dc.titleEffects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesionsen_US
dc.typeArticleen_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1136/gutjnl-2011-300154en_US
dc.identifier.pmid21917649-
dc.identifier.scopuseid_2-s2.0-84860573640en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84860573640&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume61en_US
dc.identifier.issue6en_US
dc.identifier.spage812en_US
dc.identifier.epage818en_US
dc.identifier.isiWOS:000303997800008-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridZhang, L=50162894000en_US
dc.identifier.scopusauthoridMa, JL=36077415400en_US
dc.identifier.scopusauthoridPan, KF=7102713586en_US
dc.identifier.scopusauthoridLi, JY=50161697700en_US
dc.identifier.scopusauthoridShen, L=35976895300en_US
dc.identifier.scopusauthoridLiu, WD=50162047000en_US
dc.identifier.scopusauthoridFeng, GS=55192849700en_US
dc.identifier.scopusauthoridZhang, XD=55206340500en_US
dc.identifier.scopusauthoridLi, J=36062545100en_US
dc.identifier.scopusauthoridLu, AP=7202481215en_US
dc.identifier.scopusauthoridXia, HHX=8757161400en_US
dc.identifier.scopusauthoridLam, S=7402279473en_US
dc.identifier.scopusauthoridYou, WC=18041451900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats